Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRITAM vs KHAPZORY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.
Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.
Adjunctive therapy for partial-onset seizures,Myoclonic seizures in JME,Primary generalized tonic-clonic seizures
Community-acquired bacterial pneumonia (CABP) in adults,Off-label: None established
SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.
KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.
Terminal half-life: 6–8 hours; clinical context: requires twice-daily dosing for stable serum concentrations
Terminal elimination half-life: 15-20 hours; clinical context: supports once-daily dosing
Hydrolysis by esterases in blood and tissues to carboxylic acid metabolite (ucb L057); not CYP450 dependent.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6 and CYP2C8; also undergoes conjugation and oxidation.
Renal: 66% unchanged; hepatic metabolism: 24% (inactive metabolites); fecal: negligible (<1%)
Renal: 90% as unchanged drug; fecal: <5% as metabolites
<10% bound; primarily to albumin (minimal binding)
90-95% bound to albumin
0.7–1.1 L/kg; approximates total body water, indicating extensive distribution into tissues
0.3-0.4 L/kg; clinical meaning: distributes primarily into extracellular fluid
Oral immediate-release: 100%; oral extended-release: approximately 100% relative to immediate-release
Oral: 70-85%
Cr Cl >80 m L/min: 500-1500 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 50-80: 500-1000 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 30-50: 250-750 mg BID (IR) or 500-1500 mg once daily (XR); Cr Cl <30: 250-500 mg BID (IR) or 500-1000 mg once daily (XR); ESRD on dialysis: 500-1000 mg once daily (IR) with supplemental dose after dialysis.
Cr Cl ≥60 m L/min: 25 mg daily. Cr Cl 30-60 m L/min: 10 mg daily. Cr Cl <30 m L/min (not requiring dialysis): 15 mg every 48 hours. Cr Cl <30 m L/min (requiring dialysis): 5 mg once daily; on dialysis days, administer after dialysis.
Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required; severe hepatic impairment (Child-Pugh C): use with caution; no specific dose reduction recommended, but monitor for adverse effects.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Initiate at 10 mg daily. Child-Pugh Class C: Initiate at 5 mg daily; may titrate based on tolerance.
For immediate-release: age 1 month to <6 months: 7 mg/kg/dose BID initially, titrate to 21 mg/kg/dose BID; age 6 months to <4 years: 10 mg/kg/dose BID initially, titrate to 25 mg/kg/dose BID; age 4 to <16 years: 10 mg/kg/dose BID initially, titrate up to 30 mg/kg/dose BID (max 1500 mg/day). For extended-release: only for ≥12 years: 1000 mg once daily initially, titrate to 2000 mg once daily.
Safety and efficacy not established for patients <18 years; no recommended dosing.
Consider age-related renal impairment; adjust dose based on Cr Cl per renal adjustment. Start at lower end of dosing range; monitor for sedation, dizziness, and falls.
No specific dose adjustment based on age alone; adjust for renal function as per renal adjustment guidelines; monitor for myelosuppression, thromboembolic events, and peripheral neuropathy more frequently.
No FDA black box warning.
None
Behavioral abnormalities (psychosis, aggression, suicidal ideation),Somnolence and fatigue,Dermatological reactions (e.g., Stevens-Johnson syndrome),Hematologic abnormalities,Withdrawal seizures on abrupt discontinuation
QTc interval prolongation (avoid in patients with known QTc prolongation, electrolyte disturbances, or concurrent use of QTc-prolonging agents),Hepatotoxicity (monitor liver function tests; discontinue if signs of liver injury occur),Clostridioides difficile-associated diarrhea (CDAD),Hypersensitivity reactions including anaphylaxis,Avoid use in patients with moderate to severe hepatic impairment (Child-Pugh B or C)
Hypersensitivity to levetiracetam or any component of Spritam
Hypersensitivity to lefamulin or any component of the formulation,Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) reduces lefamulin exposure; avoid coadministration
No significant food interactions. SPRITAM can be taken with or without food. A high-fat meal may slightly delay absorption but does not affect overall exposure. Avoid grapefruit juice? Not required; no known interaction with grapefruit. Alcohol may potentiate CNS depression and should be avoided.
No significant food interactions known. Avoid alcohol as it may increase risk of methotrexate toxicity.
Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, when used in polytherapy, but monotherapy may have a lower risk. Data from human pregnancy registries suggest a risk of major birth defects of 1.5-2.4% with monotherapy, compared to a baseline risk of 2-4%. In the second and third trimesters, exposure may lead to decreased fetal growth and transient neonatal effects such as sedation, withdrawal symptoms, and hypotonia. Levetiracetam is not highly protein-bound and crosses the placenta with a cord-to-maternal plasma ratio close to 1.
KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. Theoretically, no known teratogenic effect in any trimester.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is about 1-3% of maternal weight-adjusted dose, which is considered low. Limited data suggest no adverse effects on infant development. However, due to potential for lethargy and poor feeding, breastfeeding should be monitored. The benefits of breastfeeding likely outweigh risks for most infants.
Levonorgestrel is excreted into human milk; estimated infant dose < 1% of maternal dose. M/P ratio not reported. Generally considered compatible with breastfeeding.
Pregnancy can alter levetiracetam pharmacokinetics, with increased clearance and reduced serum concentrations in the second and third trimesters. Dose adjustments may be necessary to maintain seizure control. Therapeutic drug monitoring is recommended, with target trough levels at the lower end of the therapeutic range (12-46 mcg/m L) to minimize fetal exposure while ensuring efficacy. Postpartum, clearance returns to baseline, and doses should be reduced accordingly.
Not indicated for use during pregnancy. No dose adjustment applicable.
SPRITAM (levetiracetam) is a racetam anticonvulsant with a unique mechanism of action (SV2A binding). It exhibits linear pharmacokinetics with rapid oral absorption. No therapeutic drug monitoring required due to wide therapeutic index. Adjust dose in renal impairment (Cr Cl <80 m L/min). Free fraction of levetiracetam is not affected by hepatic impairment. Titrate slowly to reduce CNS side effects (somnolence, dizziness). Abrupt discontinuation may increase seizure frequency. Available in immediate-release tablets.
KHAPZORY (levoleucovorin) is used as a rescue agent after high-dose methotrexate therapy to prevent severe toxicity. Monitor serum methotrexate levels closely; administer leucovorin until methotrexate level is <5×10^-8 M. Adjust dose in renal impairment. Not interchangeable with folic acid.
Take SPRITAM exactly as prescribed; do not stop suddenly.,May cause dizziness or drowsiness; avoid driving until effects are known.,Monitor for mood changes, depression, or suicidal thoughts.,Report any skin rash or signs of allergic reaction immediately.,Use reliable contraception if applicable (no known major interaction with hormonal contraceptives).,Swallow tablets whole; do not crush or chew.,Store at room temperature, away from moisture.
Take this medication exactly as prescribed, usually every 6 hours for a set number of doses.,Do not skip doses, as this may increase the risk of methotrexate toxicity.,Inform your doctor if you experience shortness of breath, rash, or signs of allergic reaction.,Keep all appointments for blood tests to monitor methotrexate levels.,Avoid taking folic acid supplements unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRITAM vs KHAPZORY, answered by our medical review team.
SPRITAM is a Antiepileptic that works by Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.. KHAPZORY is a Antiepileptic that works by Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRITAM and KHAPZORY depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRITAM is: SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.. The standard adult dose of KHAPZORY is: KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRITAM and KHAPZORY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRITAM is classified as Category C. Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, . KHAPZORY is classified as Category C. KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. The. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.